Holen Sie sich die Stockscreener-App
207.35
0.04%
-0.09
Vorhandelsmarkt:
202.18
-5.17
-2.49%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$207.44
Offen:
$207.48
24-Stunden-Volumen:
567.17K
Relative Volume:
0.63
Marktkapitalisierung:
$22.95B
Einnahmen:
$11.28B
Nettoeinkommen (Verlust:
$1.07B
KGV:
22.87
EPS:
9.0657
Netto-Cashflow:
$1.33B
1W Leistung:
-2.86%
1M Leistung:
+2.11%
6M Leistung:
+15.22%
1J Leistung:
+23.36%
1-Tages-Spanne:
$207.01
$210.76
1-Wochen-Bereich:
$206.34
$219.20
52-Wochen-Spanne:
$164.65
$219.20
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, NTRA, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
207.35 | 22.95B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
528.51 | 196.41B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
200.16 | 141.67B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
564.21 | 44.51B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
272.89 | 39.08B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
134.04 | 37.86B | 7.23B | 1.41B | 1.09B | 4.979 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Quest Diagnostics stock holds steady as diagnostics demand supports long-term growth - Ad Hoc News
Quest Diagnostics (NYSE:DGX) Offers a Secure and Sustainable Dividend with Strong Profitability - ChartMill
Quest Diagnostics (DGX) Proxy filing Summary - Quartr
Quest Diagnostics (DGX) Q4 2025 earnings summary - Quartr
Marijuana drives half of 2025 worker hair drug positives as fentanyl rates fall - Stock Titan
Quest Diagnostics stock stays supported by steady diagnostics demand - Ad Hoc News
Quest Diagnostics steadies its business model as demand for testing evolves - Ad Hoc News
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Quest Diagnostics updates digital tools as testing demand evolves - Ad Hoc News
Quest Diagnostics Incorporated Integrates Oncology Test Access with Flatiron Health Oncoemr for American Oncology Network - marketscreener.com
Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI - marketscreener.com
Quest Diagnostics (DGX) Q4 2024 earnings summary - Quartr
Quest Diagnostics Inc. stock outperforms competitors despite losses on the day - MarketWatch
Quest Diagnostics highlights its diagnostics role as investors assess the health services sector - ad-hoc-news.de
Quest Diagnostics stock steady as investors await the next catalyst - Ad Hoc News
Quest Diagnostics Quantiferon-TB Gold Pluslab test quietly underpins US tuberculosis screening - ad-hoc-news.de
Quest Diagnostics highlights long-term testing role in U.S. healthcare - ad-hoc-news.de
DGXQuest Diagnostics Inc Volatility & Greeks - Finviz
Quest Diagnostics Incorporated (DGX) hits fresh high: Is there still room to run? - MSN
If You Invested $1,000 in Quest Diagnostics Inc (DGX) - Stock Titan
Quest Diagnostics outlines its role in medical testing as investors weigh long-term demand - ad-hoc-news.de
Quest Diagnostics highlights its role in US healthcare. The stock reflects a stable diagnostics busi - Ad Hoc News
Director Timothy Wentworth receives 144 DGX phantom units as deferred pay - Stock Titan
Quest Diagnostics steadies after recent volatility as investors focus on core testing business - ad-hoc-news.de
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Fund Update: 111,974 QUEST DIAGNOSTICS (DGX) shares added to EASTERN BANK portfolio - Quiver Quantitative
Quest Diagnostics's Q2 2026 Earnings: What to Expect - inkl
Quest Diagnostics (DGX) Q1 2025 earnings summary - Quartr
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics earnings calendar in focus, shares trade steadily on the NYSE - Ad Hoc News
Price to earnings forward of Quest Diagnostics Incorporated – NYSE:DGX - TradingView
Quest Diagnostics highlights long-term strategy, shares hold near recent highs - ad-hoc-news.de
ETFs Investing in Quest Diagnostics Incorporated Stocks - TradingView
Quest Diagnostics Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Quest Diagnostics (DGX) Wins Nationwide Haystack MRD Access And Expands Into Psychiatry - Yahoo Finance
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Quest Diagnostics Incorporated Actuals & Estimates (NYSE:DGX) - TradingView
Days After Launch, Attunio Health Expands Precision Psychiatry Infrastructure with Quest Diagnostics and Getlabs - Morningstar
DGX Forecast — Price Target — Prediction for 2027 - TradingView
Quest Diagnostics Inc (DGX) Stock Up 3.0% but GF Value Says Over - GuruFocus
Quest Diagnostics Receives New York Clearance for Haystack MRD Test - marketscreener.com
Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing - PR Newswire
Quest Diagnostics updates 2025 guidance, shares trade near record valuation levels - Ad-hoc-news.de
New York clears Quest Diagnostics' cancer recurrence test statewide - Stock Titan
Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now? - TradingView
Quest Diagnostics Prevails in Appeal Over 401(k) Fund Options - Bloomberg Law News
Quest Diagnostics StockWeekly outlook with earnings ahead - AD HOC NEWS
Is Quest Diagnostics Stock Underperforming the S&P 500? - inkl
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Study: UTI bacteria resist three common oral antibiotics - Stock Titan
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.26%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):